Source Count: 21 | Weighted Score: 45 | Source Confidence: [5/5] | Primary Tier: 2 | Last Updated: March 14, 2026
Keywords: ibogaine, iboga, Tabernanthe iboga, Bwiti, addiction interruption, opioid withdrawal, psychedelic therapy, African plant medicine, hallucinogen, indole alkaloid, MAPS, Schedule I, visionary experience
Category Tags: altered-states, ethnobotany, addiction, psychedelic-medicine, African-traditions
Cross-References: Y_1_01 — Psychedelics · X_2_11 — Ethnobotanical Pharmacology · W_4_03 — West African Civilizations

QUICK SUMMARY

Ibogaine is a naturally occurring psychoactive indole alkaloid derived from the root bark of the West African shrub Tabernanthe iboga, which has been used for centuries in the Bwiti spiritual tradition of Gabon, Cameroon, and the Republic of Congo as a sacramental visionary medicine — central to initiation ceremonies that involve prolonged visionary states lasting 24–72 hours. In the modern West, ibogaine has attracted intense scientific and clinical interest for its reported ability to interrupt opioid addiction — dramatically reducing withdrawal symptoms and cravings, sometimes after a single dose. This property was first observed by Howard Lotsof (1962), a heroin-addicted young American who noticed that after taking ibogaine, his withdrawal symptoms and desire for heroin vanished for months. Ibogaine's pharmacology is extraordinarily complex — it acts on multiple neurotransmitter systems simultaneously (NMDA receptors, kappa-opioid receptors, serotonin transporters, sigma receptors, nicotinic receptors) and is metabolized to noribogaine, a long-acting metabolite thought to be responsible for the sustained anti-addictive effects. Clinical case series and observational studies have reported significant reductions in opioid withdrawal severity and craving, but ibogaine also carries significant cardiac risk (QT prolongation, arrhythmias) and has been associated with a number of fatalities. Ibogaine remains a Schedule I substance in the United States and is unregulated or restricted in most countries, though ibogaine-assisted treatment clinics operate in Mexico, New Zealand, Brazil, and several other jurisdictions. Rigorous randomized controlled trials are limited, and the field remains caught between compelling anecdotal and observational evidence, serious safety concerns, and regulatory barriers.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Botanical and Cultural Origins

• Tabernanthe iboga: an evergreen shrub native to the tropical rainforests of Central West Africa (Gabon, Cameroon, Republic of Congo, Equatorial Guinea); the root bark contains ibogaine (the principal alkaloid) along with dozens of related alkaloids (ibogamine, tabernanthine, voacangine)
• Bwiti: an animist spiritual tradition of the Fang, Mitsogo, and related peoples of Gabon — iboga is the central sacrament of Bwiti initiation ceremonies, in which initiates consume large doses of root bark scrapings and undergo prolonged (24–72 hour) visionary experiences described as encounters with ancestors, death-and-rebirth experiences, and spiritual instruction; the Bwiti tradition predates European contact and has been practiced for centuries
• In 2000, the Gabonese government declared iboga a national cultural treasure

1.2 Pharmacology

• Ibogaine is pharmacologically unusual — it interacts with multiple receptor systems:
• NMDA glutamate receptor antagonist
• Kappa-opioid receptor agonist
• Serotonin transporter inhibitor
• Sigma-2 receptor agonist
• Nicotinic acetylcholine receptor antagonist
• Ibogaine is metabolized in the liver (CYP2D6) to noribogaine (12-hydroxyibogamine), which has a much longer half-life (24–72 hours vs. 4–7 hours for ibogaine) and is thought to maintain anti-craving effects
• Cardiac risk: ibogaine prolongs the QT interval on ECG, creating risk of potentially fatal cardiac arrhythmias (torsades de pointes); fatalities have been reported, particularly in individuals with pre-existing cardiac conditions or those taking other QT-prolonging drugs

1.3 Addiction Interruption Evidence

• Howard Lotsof (1962): self-administered ibogaine while addicted to heroin; reported complete cessation of withdrawal symptoms and absence of cravings for several months; subsequently devoted his life to promoting ibogaine research and founded NDA International
• Observational studies: Mash et al. (2000, 2018) reported significant reductions in opioid withdrawal scores (Objective Opiate Withdrawal Scale) and sustained opioid abstinence in open-label, non-randomized studies in St. Kitts; Noller et al. (2018) — prospective observational study in New Zealand showing significant reduction in opioid use at 12 months post-treatment
• No completed Phase III randomized controlled trials as of early 2026; several Phase I/II trials underway or planned

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Mechanisms of Anti-Addictive Action

• The prevailing hypothesis is that ibogaine's anti-addictive effects involve multiple complementary mechanisms: (1) NMDA antagonism (reducing withdrawal symptoms — similar to but distinct from ketamine); (2) kappa-opioid agonism (modulating reward circuits); (3) upregulation of glial cell-derived neurotrophic factor (GDNF — promoting dopaminergic neuron survival and plasticity); (4) the intense visionary/psychological experience itself — which many patients describe as therapeutically transformative
• The relative contribution of pharmacological versus psycho-spiritual mechanisms remains debated

2.2 Synthetic and Semi-Synthetic Derivatives

• 18-Methoxycoronaridine (18-MC): a synthetic ibogaine analog developed by Stanley Glick and Martin Kuehne — designed to retain anti-addictive properties while eliminating cardiac toxicity; animal studies promising but human clinical development has been slow
• Noribogaine itself is under investigation as a potentially safer alternative to ibogaine, with more favorable cardiac safety profile

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Universal Addiction Cure

• Claims that ibogaine can cure all forms of addiction (opioids, alcohol, cocaine, nicotine, gambling) with a single session — while evidence for opioid withdrawal interruption is strongest, evidence for other addictions is much weaker and largely anecdotal; "cure" is an overstatement, as many patients benefit from integration therapy and some relapse

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Ibogaine as Risk-Free

• [REFUTED] Claims that ibogaine treatment is completely safe if administered properly — cardiac fatalities have occurred even in medically supervised settings; the narrow therapeutic index and QT-prolongation risk are well-documented; medical screening, cardiac monitoring, and professional supervision are essential

COUNTER-ARGUMENTS AND CRITICAL PERSPECTIVES

Cardiac Toxicity Remains a Serious Concern

Ibogaine and its active metabolite noribogaine block hERG potassium channels, prolonging the QT interval and posing a risk of fatal cardiac arrhythmias (torsades de pointes). Multiple fatalities have been documented in treatment settings worldwide (Koenig & Hilber 2015; Litjens & Brunt 2016). Unlike psilocybin or MDMA, ibogaine carries an intrinsic cardiotoxic risk that cannot be fully mitigated by medical screening alone, making it fundamentally different from other psychedelic-assisted therapies in its safety profile.

No Completed Randomized Controlled Trials

As of 2025, no double-blind, randomized, placebo-controlled trial of ibogaine for opioid use disorder has been completed and published. The evidence base consists entirely of observational studies, case series, and retrospective surveys — all subject to selection bias, expectation effects, and lack of blinding. Claims of ibogaine's efficacy, while supported by consistent observational data, have not met the evidentiary standard required for regulatory approval.

Mechanism of Action Incompletely Understood

Ibogaine's pharmacology is complex, affecting multiple neurotransmitter systems (NMDA, opioid, serotonin, dopamine, sigma receptors, nicotinic acetylcholine receptors). Which of these interactions mediates the anti-addictive effect — and whether the subjective psychedelic experience is necessary for therapeutic benefit — remains unclear. The development of non-psychoactive ibogaine analogs (18-MC, tabernanthalog) proceeds on the hypothesis that the psychedelic component is separable from the therapeutic one, but this has not been definitively demonstrated.

Regulatory and Access Barriers

Ibogaine is a Schedule I controlled substance in the United States and several other countries, restricting clinical research. Treatment seekers frequently travel to unregulated clinics in Mexico, Central America, or the Caribbean, where medical oversight, emergency preparedness, and practitioner qualifications vary widely. The gap between clinical demand and regulated access creates a de facto underground treatment infrastructure with variable safety standards.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Alper, Kenneth R., Howard S | 2008 | "The Ibogaine Medical Subculture" | Journal of Ethnopharmacology | ∅ | 115.1::9–24 | Lotsof, and Charles D | ∅ | doi:10.1016/j.jep.2007.08.034 | ∅ | ∅ | Kaplan
2. Mash, Deborah C., et al. | 2001 | "Ibogaine in the Treatment of Heroin Withdrawal" | The Alkaloids: Chemistry and Biology | ∅ | 56::283–300 | ∅ | ∅ | doi:10.1016/s0099-9598(01)56012-5 | ∅ | ∅ | ∅
3. Noller, Geoffrey E., Chris M | 2018 | "Ibogaine Treatment Outcomes for Opioid Dependence from a Twelve-Month Follow-Up Observational Study" | American Journal of Drug and Alcohol Abuse | ∅ | 44.1::37–46 | Frampton, and Berra Yazar-Klosinski | ∅ | doi:10.1080/00952990.2017.1310218 | ∅ | ∅ | ∅
4. Fernandes, J | 1982 | "Bwiti: An Ethnography of the Religious Imagination in Africa" | ∅ | ∅ | ∅ | W | ∅ | doi:10.2307/1160689 | ∅ | ∅ | Princeton: Princeton University Press
5. Glick, Stanley D., et al | 2006 | "18-Methoxycoronaridine (18-MC): A Novel Iboga Alkaloid Congener" | CNS Drug Reviews | ∅ | 12.2::29–42 | ∅ | ∅ | doi:10.1111/j.1527-3458.1999.tb00084.x | ∅ | ∅ | ∅
6. Koenig, Xaver; Karlheinz Hilber | 2015 | "The Anti-Addiction Drug Ibogaine and the Heart" | Molecules | ∅ | 20.2::2208–2228 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
7. Samorini, Giorgio | 1995 | "The Bwiti Religion and the Psychoactive Plant Tabernanthe Iboga" | Integration | ∅ | 5::105–114 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Brown, Thomas K | 2013 | "Ibogaine in the Treatment of Substance Dependence" | Current Drug Abuse Reviews | ∅ | 6.1::3–16 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Popik, Piotr, et al | 1999 | "Pharmacology of Ibogaine and Ibogaine-Related Alkaloids" | The Alkaloids: Chemistry and Biology | ∅ | 52::197–231 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
10. Winkelman, Michael J | 2014 | "Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca" | Current Drug Abuse Reviews | ∅ | 7.2::101–116 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
11. Belgers, Mirte, et al. e826 | 2016 | "Ibogaine and Addiction in the Animal Model, a Systematic Review and Meta-Analysis" | Translational Psychiatry | ∅ | 6:: | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
12. Litjens, Ralf P | 2016 | "How Toxic Is Ibogaine?" | Clinical Toxicology | ∅ | 54.4::297–302 | W., and Tanno F | ∅ | ∅ | ∅ | ∅ | P; Brunt
13. Mash, Deborah C., et al | 2000 | "Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures" | Annals of the New York Academy of Sciences | ∅ | 914::394–401 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
14. Malcolm, Benjamin J., et al | 2018 | "Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine" | Journal of Psychoactive Drugs | ∅ | 50.3::256–263 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
15. Bogenschutz, Michael P.; Matthew W | 2016 | "Classic Hallucinogens in the Treatment of Addictions" | Progress in Neuro-Psychopharmacology and Biological Psychiatry | ∅ | 64::250–258 | Johnson | ∅ | ∅ | ∅ | ∅ | ∅
16. dos Santos, Rafael G., et al | 2016 | "Antidepressive, Anxiolytic, and Antiaddictive Effects of Ayahuasca, Psilocybin and Lysergic Acid Diethylamide (LSD): A Systematic Review of Clinical Trials Published in the Last 25 Years" | Therapeutic Advances in Psychopharmacology | ∅ | 6.3::193–213 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
17. Johnson, Matthew W., et al | 2019 | "Classic Psychedelics: An Integrative Review of Epidemiology, Therapeutics, Mystical Experience, and Brain Network Function" | Pharmacology & Therapeutics | ∅ | 197::83–102 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
18. Vollenweider, Franz X.; Michael Kometer | 2010 | "The Neurobiology of Psychedelic Drugs: Implications for the Treatment of Mood Disorders" | Nature Reviews Neuroscience | ∅ | 11.9::642–651 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
19. Carhart-Harris, Robin L.; David J | 2017 | "Serotonin and Brain Function: A Tale of Two Receptors" | Journal of Psychopharmacology | ∅ | 31.9::1091–1120 | Nutt | ∅ | ∅ | ∅ | ∅ | ∅
20. Halberstadt, Adam L.; Mark A | 2011 | "Multiple Receptors Contribute to the Behavioral Effects of Indoleamine Hallucinogens" | Neuropharmacology | ∅ | 61.3::364–381 | Geyer | ∅ | ∅ | ∅ | ∅ | ∅
21. Passie, Torsten, et al | 2008 | "The Pharmacology of Lysergic Acid Diethylamide: A Review" | CNS Neuroscience & Therapeutics | ∅ | 14.4::295–314 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 11, 2026

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/s0099-9598(01)56012-5. Corpus hygiene campaign, Phase 4, 2026-07-29.